292 related articles for article (PubMed ID: 31462263)
1. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
9. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
Besada E
BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
[TBL] [Abstract][Full Text] [Related]
10. Hypogammaglobulinemia in pediatric systemic lupus erythematosus.
Lim E; Tao Y; White AJ; French AR; Cooper MA
Lupus; 2013 Nov; 22(13):1382-7. PubMed ID: 24106215
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C; Delbet JD; Decramer S; Boyer O; Hogan J; Ulinski T
Pediatr Nephrol; 2020 Mar; 35(3):455-462. PubMed ID: 31705306
[TBL] [Abstract][Full Text] [Related]
12. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Barmettler S; Ong MS; Farmer JR; Choi H; Walter J
JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343
[TBL] [Abstract][Full Text] [Related]
13. [Prevalence of persistent hypogammaglobulinemia in patients with autoimmune rheumatic disease who received treatment with Rituximab in a national medical center in Mexico].
Fraga-Olvera A; Saavedra-Salinas MÁ; Beltrán-Mendoza JQ; Mendieta-Flores E
Rev Alerg Mex; 2023 Apr; 69(4):171-182. PubMed ID: 37218045
[TBL] [Abstract][Full Text] [Related]
14. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
Podestà MA; Mescia F; Ricchiuto A; Smith R; Tedesco M; Cassia MA; Holle J; Sinico RA; Bruchfeld A; Gunnarsson I; Ohlsson S; Baslund B; Hruskova Z; Tesar V; Sabiu G; Gallieni M; Cid MC; Vaglio A; Harper L; Cozzolino M; Scolari F; Jayne D; Alberici F
Rheumatology (Oxford); 2023 Aug; 62(8):2850-2854. PubMed ID: 36562566
[TBL] [Abstract][Full Text] [Related]
16. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
Evangelatos G; Fragoulis GE; Klavdianou K; Moschopoulou M; Vassilopoulos D; Iliopoulos A
Rheumatology (Oxford); 2021 May; 60(5):2375-2382. PubMed ID: 33175958
[TBL] [Abstract][Full Text] [Related]
17. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
18. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era.
Chiou FK; Beath SV; Patel M; Gupte GL
Pediatr Transplant; 2019 Sep; 23(6):e13519. PubMed ID: 31209964
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
[TBL] [Abstract][Full Text] [Related]
20. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases.
Boumaza X; Lafaurie M; Treiner E; Walter O; Pugnet G; Martin-Blondel G; Biotti D; Ciron J; Constantin A; Tauber M; Puisset F; Moulis G; Alric L; Renaudineau Y; Chauveau D; Sailler L
Int Immunopharmacol; 2023 Jul; 120():110342. PubMed ID: 37276827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
